Drugs / MVA-BN-WEV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04131595 | Oct 2019 → Jul 2020 | viral encephalitis | Bavarian Nordic | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06899802 Comparator | Mar 2025 → Feb 2027 expected | encephalitis | Bavarian Nordic | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MVA-BN-WEV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04131595 ↗ |
| Known as | MVA-mBN396 | “MVA-mBN396 (common name MVA-BN-WEV vaccine), is a highly attenuated, live recombinant virus” NCT06899802 ↗ |
| Modality | Vaccine | “A novel multivalent MVA-BN-WEV vaccine encodes the envelope surface proteins of the 3 viruses” PMID 38494412 ↗ Mar 2024 |